Shop
Cart Details

Erythromycin 5Mg 3.5G Oo

  • Manufacturer Name : Paddock Laboratories
  • MFG # : 00574402435
  • NDC : 00574402435
  • Distributor Name : Curascript
PID UOM Price Qty

You are not eligible to purchase this product. Please contact your account manager for more information.

Register For Member Price

 

Additional Information

Product NameErythromycin 0.5% Ophthalmic Ointment, 3.5 G
ManufacturerPerrigo
MFG # 00574-4024-35
Active Ingredient Erythromycin
Concentration 0.5%
Spectrum of Activity Effective against a wide range of bacteria
Administration Applied topically to the eye
Indication Treatment of bacterial eye infections
Antibiotic Class Macrolide antibiotic
Application Ophthalmic use
Sterility Sterile
Container Size 3.5 grams
Form Ointment

Description

Erythromycin 0.5% Ophthalmic Ointment is an ophthalmic antibiotic medication used for the treatment of bacterial eye infections. Each 3.5-gram container contains 0.5% erythromycin, a macrolide antibiotic effective against a wide range of bacteria. The ointment is sterile and designed for topical application to the eye, typically administered 3 to 4 times daily until the infection resolves.

Packaged in a tube or container for easy dispensing, this ointment should be stored at room temperature and applied cautiously to avoid contact with the eyes and mucous membranes. While generally well-tolerated, there is a potential for adverse reactions such as irritation or allergic responses. Erythromycin ophthalmic ointment is suitable for use in pediatric patients under supervision, but caution should be exercised in geriatric patients. Pregnant and nursing mothers should use this medication only if clearly needed and under medical supervision. Perrigo manufactures this ointment, which is CE marked and FDA approved for quality and safety assurance in clinical practice.

Frequently Asked Questions(FAQs)

The cost of Erythromycin 5Mg 3.5G Oo is available for registerd members only .
Erythromycin 5Mg 3.5G Oo is manufactured by Paddock Laboratories.
Read More

Subscribe to Our Newsletter